{"title":"Synergistic approach of salt formation and polymer-mediated stabilization to enhance the biopharmaceutical performance of Mebendazole","authors":"Ridhima Singh , Mehak Juneja , Vanshul Saini, Roshni Malviya, Rutuja Kshirsagar, Mahesh Kashyap, Abhay T. Sangamwar","doi":"10.1016/j.ejpb.2025.114809","DOIUrl":null,"url":null,"abstract":"<div><div>Mebendazole (MBZ), a brick dust molecule with poor aqueous solubility tends to precipitate at intestinal pH, impeding its gastrointestinal absorption. Moreover, the amorphous MBZ tends to recrystallize in conventional amorphous solid dispersion (ASD) during long-term storage, reducing its physical stability and solubility. The present investigation explored amorphous salt solid dispersion (ASSD), an emerging approach combining salt formation with ASD, where the counterion and polymer are crucial in forming a stable supersaturated system. The maximal supersaturation holding capacity of hydroxypropyl methylcellulose acetate succinate polymer and its potential to lower the melting endotherm of MBZ demonstrate its suitability for ASSD preparation, via acid-base reaction between HCl and MBZ. P-XRD and DSC confirmed the amorphization of MBZ in ASSD, exhibiting a higher T<sub>g</sub> and improved physical stability. <sup>1</sup>H NMR and FTIR spectroscopy confirmed the protonation of nitrogen during salt formation, with stronger salt-polymer interactions that stabilized the amorphous MBZ in ASSD, preventing recrystallization for 12 months, compared to ASD. Additionally, ASSD exhibited synergistic enhancement in solubility (7.58-folds) and dissolution (11.17-folds) of MBZ, which translated into <em>in vivo</em> studies, demonstrating 2.99-folds increase in C<sub>max</sub>. Hence, findings revealed ASSD as a potential approach for augmenting the biopharmaceutical performance of MBZ over ASD.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"214 ","pages":"Article 114809"},"PeriodicalIF":4.3000,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmaceutics and Biopharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0939641125001869","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Mebendazole (MBZ), a brick dust molecule with poor aqueous solubility tends to precipitate at intestinal pH, impeding its gastrointestinal absorption. Moreover, the amorphous MBZ tends to recrystallize in conventional amorphous solid dispersion (ASD) during long-term storage, reducing its physical stability and solubility. The present investigation explored amorphous salt solid dispersion (ASSD), an emerging approach combining salt formation with ASD, where the counterion and polymer are crucial in forming a stable supersaturated system. The maximal supersaturation holding capacity of hydroxypropyl methylcellulose acetate succinate polymer and its potential to lower the melting endotherm of MBZ demonstrate its suitability for ASSD preparation, via acid-base reaction between HCl and MBZ. P-XRD and DSC confirmed the amorphization of MBZ in ASSD, exhibiting a higher Tg and improved physical stability. 1H NMR and FTIR spectroscopy confirmed the protonation of nitrogen during salt formation, with stronger salt-polymer interactions that stabilized the amorphous MBZ in ASSD, preventing recrystallization for 12 months, compared to ASD. Additionally, ASSD exhibited synergistic enhancement in solubility (7.58-folds) and dissolution (11.17-folds) of MBZ, which translated into in vivo studies, demonstrating 2.99-folds increase in Cmax. Hence, findings revealed ASSD as a potential approach for augmenting the biopharmaceutical performance of MBZ over ASD.
期刊介绍:
The European Journal of Pharmaceutics and Biopharmaceutics provides a medium for the publication of novel, innovative and hypothesis-driven research from the areas of Pharmaceutics and Biopharmaceutics.
Topics covered include for example:
Design and development of drug delivery systems for pharmaceuticals and biopharmaceuticals (small molecules, proteins, nucleic acids)
Aspects of manufacturing process design
Biomedical aspects of drug product design
Strategies and formulations for controlled drug transport across biological barriers
Physicochemical aspects of drug product development
Novel excipients for drug product design
Drug delivery and controlled release systems for systemic and local applications
Nanomaterials for therapeutic and diagnostic purposes
Advanced therapy medicinal products
Medical devices supporting a distinct pharmacological effect.